Consistent with our current bioinformatic analysis of the immune cell landscape in the TCGA database, a recent comprehensive evaluation of the role of FASN in tumor immune infiltration and prognostic value for immunotherapy revealed a negative correlation of FASN with immune checkpoints (e.g., PD-1, PD-L1, CTLA-4) as well as a more favorable response to anti-PD-L1 treatment in FASN-overexpressing tumors [90]. The gene discussed is CTLA4; the disease is neoplasm.